In MM mice, bortezomib worsened systolic dysfunction induced by MM itself, resulting in a highly significant reduction of LVEF (to 31% vs. 49% in healthy animals treated with bortezomib and 43% in untreated MM animals) and IVCT ( Figure 3 A and 3B, respectively), without affecting diastolic parameters ( Figure 3 E,F).
← all excerpts
Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma.
1
—
—